MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois. Show more

444 West Lake Street, Chicago, IL, 60606, United States

Biotechnology

Healthcare

Market Cap

74.78M

52 Wk Range

$0.87 - $3.19

Previous Close

$1.23

Open

$1.26

Volume

450,377

Day Range

$1.24 - $1.30

Enterprise Value

40.37M

Cash

34.41M

Avg Qtr Burn

-5.311M

Insider Ownership

14.26%

Institutional Own.

21.58%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ateganosine (THIO; 6-thio-2'-deoxyguanosine) Details Non-small cell lung carcinoma (NSCLC 3L)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ateganosine (THIO; 6-thio-2'-deoxyguanosine) Details Non-small cell lung carcinoma (NSCLC 2L+)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.